Gelesis just last week drummed up a $22 million funding round, but that's not stopping the Boston-based company from registering for an initial public offering worth $60 million.
Gelesis, which makes an anti-obesity pill using a super-absorbent hydrogel to induce feelings of satiety, said the Gelesis100 pill is also designed to improve glycemic control. The company expects to launch the product in the U.S. in 2019, assuming it wins FDA approval. Gelesis100 could hit the European market a year earlier, the company said.
Help employers find you! Check out all the jobs and post your resume.
Gelesis, which makes an anti-obesity pill using a super-absorbent hydrogel to induce feelings of satiety, said the Gelesis100 pill is also designed to improve glycemic control. The company expects to launch the product in the U.S. in 2019, assuming it wins FDA approval. Gelesis100 could hit the European market a year earlier, the company said.
Help employers find you! Check out all the jobs and post your resume.
